Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
28011470
DOI
10.21873/anticanres.11285
PII: 37/1/21
Knihovny.cz E-zdroje
- Klíčová slova
- CTLA4 inhibition, GBM, Glioblastoma multiforme, PD1 inhibition, clinical trials, immune checkpoint inhibitors, immunotherapy, personalized medicine, review, targeted therapy,
- MeSH
- antitumorózní látky škodlivé účinky terapeutické užití MeSH
- cílená molekulární terapie škodlivé účinky trendy MeSH
- glioblastom genetika imunologie metabolismus terapie MeSH
- imunoterapie škodlivé účinky trendy MeSH
- inhibitory angiogeneze terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé MeSH
- monoklonální protilátky škodlivé účinky terapeutické užití MeSH
- nádorové biomarkery antagonisté a inhibitory genetika imunologie metabolismus MeSH
- nádorové mikroprostředí MeSH
- nádory mozku genetika imunologie metabolismus terapie MeSH
- signální transdukce účinky léků MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antitumorózní látky MeSH
- inhibitory angiogeneze MeSH
- inhibitory proteinkinas MeSH
- monoklonální protilátky MeSH
- nádorové biomarkery MeSH
Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor in adults with generally dismal prognosis, early clinical deterioration and high mortality. GBM is extremely invasive, characterized by intense and aberrant vascularization and high resistance to multimodal treatment. Standard therapy (surgery, radiotherapy and chemotherapy with temozolomide) has very limited effectiveness, with median overall survival of patients no longer than 15 months. Progress in genetics and epigenetics of GBM over the past decade has revealed various aberrations in cellular signaling pathways, the tumor microenvironment, and pathological angiogenesis. A number of targeted anticancer drugs, such as small-molecule kinase inhibitors and monoclonal antibodies, have been evaluated in clinical trials with newly-diagnosed, as well as recurrent GBM. Unfortunately, to date, only a single anti-angiogenic agent, bevacizumab, has been approved for the treatment of recurrent GBM in the USA and Canada. The novel possibilities of cancer immunotherapy, especially immune checkpoint inhibitors, are being evaluated in clinical trials of patients with GBM. The most recent clinical experiences with targeted therapy as well as immunotherapy of GBM are given in this review. The relative lack of success of some of these approaches recently revealed in well-designed randomized clinical trials is also discussed.
Citace poskytuje Crossref.org
